| Literature DB >> 23595090 |
Stanisław Boryczka1, Ewa Bębenek, Joanna Wietrzyk, Katarzyna Kempińska, Maria Jastrzębska, Joachim Kusz, Maria Nowak.
Abstract
A new series of betulin derivatives containing one or two pharmacophores bearing an acetylenic and carbonyl function at the C-3 and/or C-28 positions has been synthesized and characterized by ¹H- and ¹³C-NMR, IR, MS and elemental analyses. The crystal structure of 28-O-propynoylbetulin was determined by X-ray structural analysis. All new compounds, as well as betulin, were tested in vitro for their antiproliferative activity against human SW707 colorectal, CCRF/CEM leukemia, T47D breast cancer, and against murine P388 leukemia and Balb3T3 normal fibroblasts cell lines. Most of the compounds showed better cytotoxicity than betulin and cisplatin used as reference agent. 28-O-Propynoylbetulin was the most potent derivative, being over 500 times more potent than betulin and about 100 times more cytotoxic than cisplatin against the human leukemia (CCRF/CEM) cell line, with an ID₅₀ value of 0.02 μg/mL.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23595090 PMCID: PMC6270304 DOI: 10.3390/molecules18044526
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structure of betulin (1) and betulinic acid (2).
Scheme 1Synthesis of acetylenic derivatives of betulin 3–6.
Scheme 2Synthesis of betulin derivatives 7 and 8.
Figure 2Molecular structure with atomic numbering scheme of 28-O-propynoylbetulin – DMSO solvate 5a with displacement ellipsoids of 50% probability.
Cytotoxic activity of betulin (1), acetylenic betulins 3–8 and cisplatin reference compound against the cells of the tested human and murine cancer cell lines.
| Compd. | Cytotoxic activity IC50 [µg/mL] | ||||||
|---|---|---|---|---|---|---|---|
| Human | Murine | ||||||
|
|
|
|
|
|
|
| |
|
| - | - | 32.4 ± 10.7 | 10.9 ± 5.5 | 22.9 ± 15.4 | 5.5 ± 3.3 | 47.3 ± 7.9 |
|
| CH2C≡CH | - | 7.2 ± 1.7 | 3.2 ± 0.4 | 9.2 ± 7.1 | 2.9 ± 0.2 | 3.9 ± 2.8 |
|
| CH2CH2C≡CH | - | 6.9 ± 2.3 | 5.2 ± 1.4 | 22.6 ± 11.9 | 3.6 ± 1.3 | 19.5 ± 13.9 |
|
| CH2C≡CCH3 | - | 20.1 ± 5.3 | 6.8 ± 2.9 | 36.9 ± 6.3 | 5.5 ± 2.8 | 28.4 ± 17.6 |
|
| CH2CH3 | - | 6.6 ± 1.3 | 4.1 ± 0.2 | 20.8 ± 14.7 | 3.8 ± 1.9 | 19.1 ± 13.5 |
|
| CH2C≡CH | - | Neg | Neg | Neg | 33.4 ± 1.7 | Neg |
|
| CH2CH2C≡CH | - | Neg | Neg | Neg | Neg | Neg |
|
| CH2C≡CCH3 | - | Neg | Neg | Neg | 50.4 ± 31.1 | Neg |
|
| CH2CH3 | - | 69.1 ± 12.4 | 52.6 ± 8.3 | Neg | 46.8 ± 21.6 | Neg |
|
|
| C≡CH | 9.1 ± 1.9 | 0.02 ± 0.001 | 14.9 ± 3.3 | 0.4 ± 0.1 | 0.3 ± 0.05 |
|
|
| C≡CPh | Neg | 49.0 ± 9.8 | Neg | Neg | Neg |
|
|
| CH2CH3 | 12.1 ± 4.4 | 8.1 ± 0.9 | 29.2 ± 24.4 | 3.3 ± 0.8 | 32.3 ± 23.0 |
|
|
| C≡CH | 16.2 ± 4.3 | 9.9 ± 7.0 | 9.5 ± 1.9 | 31.9 ± 1.4 | 21.1 ± 2.6 |
|
|
| C≡CPh | Neg | 66.0 ± 2.8 | Neg | Neg | Neg |
|
| - | CH2CH3 | 26.6 ± 6.8 | Neg | 42.3 ± 9.4 | 68.1 ± 14.8 | Neg |
|
| - | - | 4.9 ± 0.6 | 3.4 ± 0.3 | 5.1 ± 2.5 | 12.5 ± 14.7 | 29.7 ± 35.8 |
|
| - | - | Neg | 34.1 ± 6.4 | Neg | 40.2 ± 5.0 | Neg |
|
| CH2C≡CH | - | Neg | Neg | Neg | Neg | Neg |
|
| CH2C≡CCH3 | - | Neg | Neg | Neg | 46.7 ± 16.2 | Neg |
|
| CH2CH2C≡CH | - | Neg | Neg | Neg | Neg | Neg |
|
| CH2CH3 | - | Neg | Neg | Neg | Neg | Neg |
|
| 3.1 ± 1.0 | 2.0 ± 0.5 | 2.2 ± 0.5 | 0.5 ± 0.3 | 2.7 ± 0.3 | ||
Neg – negative in the concentration used.
Figure 3Proposed mesomeric structures of propynoyl pharmacophore of 28-O-propynoylbetulin (5a).